
Metabolic Disease

Infectious Disease

Antibiotic Alternatives

Immunology

Oncology

Peter Hanson
Centrexion is developing a pipeline of non-opioid, non-addictive treatments to manage pain in people and animals. Peter started his career as a practicing veterinarian and has spent the last 21 years in industry. At Merck and then Merial he was the project leader for two global programs that led to new pain management products for osteoarthritis in dogs and horses. He subsequently held leadership roles for pharmaceutical R&D and project & portfolio management before moving to Abbott Animal Health where he was head of R&D & medical affairs. Peter received his BA and DVM from the University of Minnesota and completed a large animal surgical residency, MS and PhD at the University of Wisconsin-Madison.

Scott Brown

Kristin Bloink
Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D. She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector. She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.

Brian Kopp
Brian Kopp is a Partner at Stonehaven Consulting AG. He has 20 years of experience in Healthcare with Eli Lilly and Company, and 7 years of experience in Automotive with General Motors. Since 2007, Brian has served as CFO and V.P. of Operations and Strategy with Elanco Animal Health, a division of Eli Lilly and Company. Over this period, Elanco has grown Revenues from $700 million to over $3 billion, emerged as a top tier player in the industry, achieved top tier Operating margins, experienced significant expansion of business lines, global capabilities, and overall value. This significant growth was achieved by executing on an aggressive transformation agenda that included capitalizing on a mix of organic and inorganic opportunities. After 27 years working in increasingly relevant roles within Corporate settings, Brian is excited by the opportunity to take his experiences and insights and help Animal Health partners develop and/or realize their strategic goals.
